General Information of Drug (ID: DMOFCRY)

Drug Name
SEROTONIN Drug Info
Synonyms
serotonin; 5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5202
ChEBI ID
CHEMBL39
CAS Number
CAS 50-67-9
TTD Drug ID
DMOFCRY
VARIDT Drug ID
DR00189
INTEDE Drug ID
DR1961

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [25]
Eletriptan DMW649X Migraine 8A80 Approved [26]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [26]
Frovatriptan DM7RE8P Migraine 8A80 Approved [26]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [26]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [27]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [26]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [28]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [29]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [31]
Eletriptan DMW649X Migraine 8A80 Approved [26]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [26]
Frovatriptan DM7RE8P Migraine 8A80 Approved [26]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [32]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [33]
Almogran DM7I64Z Migraine 8A80 Approved [34]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [35]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [36]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 5A receptor (HTR5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [37]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [38]
5-CT DM260KD Discovery agent N.A. Investigative [39]
TFMPP DMAC8TP Discovery agent N.A. Investigative [40]
5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 Discovery agent N.A. Investigative [41]
MPDT DMYX31S Discovery agent N.A. Investigative [42]
5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 Discovery agent N.A. Investigative [41]
EDMT DMS3AXK Discovery agent N.A. Investigative [42]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 Discovery agent N.A. Investigative [41]
[3H]5-CT DMEAHFZ Discovery agent N.A. Investigative [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [44]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [45]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [46]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [47]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [46]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [48]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [49]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [45]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [50]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [52]
Triflupromazine DMKFQJP Nausea MD90 Approved [53]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [54]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [55]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [56]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [57]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [58]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [58]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [58]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [52]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [59]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [60]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [61]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [62]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [63]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [64]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [65]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [66]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [67]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IB-MECA DM9G5XD Psoriasis vulgaris EA90 Phase 3 [68]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [69]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [70]
CF102 DMP56WJ Hepatocellular carcinoma 2C12.02 Phase 2 [71]
SCH-442416 DMQ2K1V N. A. N. A. Phase 1 [72]
AST-004 DM5WMG7 Stroke 8B20 Phase 1 [73]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [10]
BAY 60-6583 DMTEJV1 Myocardial ischemia BA6Z Preclinical [74]
CF602 DM0ULO2 Inflammation 1A00-CA43.1 Preclinical [71]
CF502 DMQSJ20 Inflammation 1A00-CA43.1 Preclinical [71]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3B receptor (HTR3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [75]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [76]
QUIPAZINE DMPY6IG Discovery agent N.A. Investigative [7]
MESULERGINE DMKGWAH Discovery agent N.A. Investigative [77]
bilobalide DM09Z35 Discovery agent N.A. Investigative [78]
2-(4-Methyl-piperazin-1-yl)-quinoline DMB8OY6 Discovery agent N.A. Investigative [7]
BRL-24682 DMSB4EW Discovery agent N.A. Investigative [79]
6-(4-Methyl-piperazin-1-yl)-phenanthridine DM1HAWR Discovery agent N.A. Investigative [7]
trichloroethanol DMNALMF Discovery agent N.A. Investigative [80]
1-phenylbiguanide DMA4XGL Discovery agent N.A. Investigative [81]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 4 receptor (HTR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [82]
Tegaserod DM3XYD1 Irritable bowel syndrome DD91.0 Approved [83]
R0-93877 DMM4U9G Constipation DD91.1 Approved [32]
HTF 919 DM78G6F Constipation DD91.1 Approved [84]
Mosapride DM2VOQ3 N. A. N. A. Phase 4 [85]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [86]
Lintopride DMSHGWN Nausea MD90 Phase 2 [87]
TD-8954 DM3C9NV Gastrointestinal disease DE2Z Phase 2 [88]
SB-207266A DM27KFY Irritable bowel syndrome DD91.0 Phase 2 [32]
YKP-GI DM740LV Constipation DD91.1 Phase 2 [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [90]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [91]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [92]
Palonosetron DMBHMOX Nausea MD90 Approved [93]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [92]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [94]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [95]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [75]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [96]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [97]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [26]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [98]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [99]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [100]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [61]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [101]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [102]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [103]
Treximet DMU54QB Migraine 8A80 Approved [104]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [105]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [36]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [106]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [107]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [108]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [109]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [109]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [110]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [110]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [111]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [112]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [52]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [113]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [114]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [115]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [116]
Methysergide DM1EF73 Migraine 8A80 Approved [117]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [28]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [118]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [119]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [56]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [120]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [121]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [122]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [123]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [14]
Propranolol DM79NTF Angina pectoris BA40 Approved [124]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [125]
Metformin DM89QE1 Colorectal carcinoma Approved [126]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [124]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [127]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [13]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [128]
Norepinephrine DMOUC09 Alopecia ED70 Approved [13]
Methamphetamine DMPM4SK Anxiety Approved [129]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [13]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [130]
Norepinephrine DMOUC09 Alopecia ED70 Approved [13]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [131]
Metformin DM89QE1 Colorectal carcinoma Approved [132]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [22]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [148]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [149]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [150]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [152]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [153]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [154]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [155]
Epinephrine DM3KJBC Acute asthma CA23 Approved [22]
⏷ Show the Full List of 12 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Oxypertine DMYKG8R N. A. N. A. Preclinical [133]
Paroxetine DM5PVQE Anxiety disorder 6B00-6B0Z Approved [139]
Fluoxetine DM3PD2C Bipolar depression Approved [140]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [141]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [142]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [143]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [144]
Quercetin DM3NC4M Obesity 5B81 Approved [145]
Aripiprazole DM3NUMH Bipolar I disorder Approved [146]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [143]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [147]
⏷ Show the Full List of 11 Drug(s)
Drug(s) Metabolized By Monoamine oxidase type A (MAO-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [134]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [135]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [136]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [137]
Almotriptan malate DMFG5ST N. A. N. A. Approved [138]
PHENETHYLAMINE DMX0G4F Discovery agent N.A. Investigative [15]
Benzylamine DMRM6ES N. A. N. A. Investigative [15]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [148]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [156]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [157]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [158]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [159]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [160]
Ethanol DMDRQZU Chronic pain MG30 Approved [161]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [162]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [163]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [164]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [165]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [157]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [166]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [167]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [168]
Bortezomib DMNO38U Leukemia Approved [169]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [170]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [171]
Fenfluramine DM0762O Dravet syndrome 8A61.11 Phase 3 [172]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [173]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [157]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [174]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [175]
Haloperidol DM96SE0 Delirium Approved [175]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [176]
Olanzapine DMPFN6Y Bipolar depression Approved [177]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [178]
Arsenic DMTL2Y1 N. A. N. A. Approved [179]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [180]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-8 (CXCL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [181]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [182]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [183]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [184]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [185]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [186]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [187]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [188]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [189]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [187]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [145]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [190]
Haloperidol DM96SE0 Delirium Approved [191]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [192]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [193]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [194]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [195]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [176]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [195]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [196]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [197]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [198]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [199]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [200]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [201]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [202]
Gefitinib DM15F0X Colon adenocarcinoma Approved [203]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [204]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [205]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [206]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [197]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [207]
Paclitaxel DMLB81S Breast carcinoma Approved [208]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [209]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [196]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [157]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [210]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [199]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [200]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [211]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [212]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [213]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [214]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [215]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [216]
Capsaicin DMGMF6V Back pain ME84.Z Approved [217]
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [218]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [219]
Bryostatin-1 DM1JOXY Alzheimer disease 8A20 Phase 2 [220]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [210]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [221]
Selenium DM25CGV N. A. N. A. Approved [222]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [223]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [224]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [225]
Quercetin DM3NC4M Obesity 5B81 Approved [145]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [226]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [227]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [228]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [141]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [229]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [230]
Leflunomide DMR8ONJ Arthritis FA20 Approved [231]
Clodronate DM9Y6X7 Hypercalcaemia 5B91.0 Approved [230]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [230]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [192]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [232]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [230]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [230]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Poly polymerase 1 (PARP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [160]
Gefitinib DM15F0X Colon adenocarcinoma Approved [233]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [234]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [235]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [236]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [237]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [236]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [238]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [239]
Methotrexate DM2TEOL Anterior urethra cancer Approved [240]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [241]
Amphetamine DMSZQAK Attention deficit hyperactivity disorder 6A05.Z Approved [242]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [243]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [166]
Testosterone DM7HUNW Hot flushes GA30 Approved [244]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [244]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Dextroamphetamine DMMIHVP Attention deficit hyperactivity disorder 6A05.Z Approved [245]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [246]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [247]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [248]
Selenium DM25CGV N. A. N. A. Approved [222]
Methotrexate DM2TEOL Anterior urethra cancer Approved [249]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [250]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [251]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [252]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [253]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [254]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [255]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [256]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [22]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [22]
Norepinephrine DMOUC09 Alopecia ED70 Approved [22]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [257]
Quercetin DM3NC4M Obesity 5B81 Approved [145]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [258]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [192]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [259]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [260]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [167]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [261]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [193]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [155]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [262]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [263]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [264]
Formaldehyde DM7Q6M0 Discovery agent N.A. Investigative [265]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [2]
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Inhibitor [3]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [4]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [2]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Inhibitor [5]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Inhibitor [6]
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Inhibitor [7]
5-HT 3B receptor (HTR3B) TTR6K75 5HT3B_HUMAN Inhibitor [7]
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Inhibitor [6]
5-HT 5A receptor (HTR5A) TTRUFDT 5HT5A_HUMAN Inhibitor [8]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [9]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Inhibitor [8]
Adenosine A3 receptor (ADORA3) TTJFY5U AA3R_HUMAN Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium-dependent serotonin transporter (SLC6A4) DTAV4SY SC6A4_HUMAN Substrate [11]
Equilibrative nucleoside transporter 4 (SLC29A4) DT3EAQP S29A4_HUMAN Substrate [12]
Vesicular amine transporter 2 (SLC18A2) DTT7VPB VMAT2_HUMAN Substrate [13]
Vesicular amine transporter 1 (SLC18A1) DTM953D VMAT1_HUMAN Substrate [13]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Monoamine oxidase type A (MAO-A) Main DME DERE4TU AOFA_HUMAN Substrate [15]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 1D (HTR1D) OTLS74AF 5HT1D_HUMAN Regulation of Drug Effects [16]
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Drug Response [17]
5-hydroxytryptamine receptor 2B (HTR2B) OTM1AD9J 5HT2B_HUMAN Protein Interaction/Cellular Processes [18]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) OTJC60Q7 THIL_HUMAN Gene/Protein Processing [19]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Drug Response [20]
Chromaffin granule amine transporter (SLC18A1) OT01OALS VMAT1_HUMAN Regulation of Drug Effects [21]
Equilibrative nucleoside transporter 4 (SLC29A4) OTWTZXMX S29A4_HUMAN Regulation of Drug Effects [22]
Interleukin-12 subunit beta (IL12B) OT0JF8A3 IL12B_HUMAN Protein Interaction/Cellular Processes [23]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Gene/Protein Processing [23]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [24]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5).
2 Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
3 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
4 Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16.
5 Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
6 Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
7 Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
8 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
9 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7.
10 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
11 Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet. 2009 Dec;2(6):614-20.
12 Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014 Aug 13;5:43.
13 SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
14 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
15 Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
16 Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet. 2007 Apr;121(2):243-56. doi: 10.1007/s00439-006-0301-3. Epub 2007 Jan 3.
17 Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
18 A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem. 1998 Dec 17;41(26):5148-9. doi: 10.1021/jm9803525.
19 Serotonin acts as an up-regulator of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-macrophages. Atherosclerosis. 2006 Jun;186(2):275-81. doi: 10.1016/j.atherosclerosis.2005.08.007. Epub 2005 Sep 12.
20 Rose Essential Oil Delayed Alzheimer's Disease-Like Symptoms by SKN-1 Pathway in C. elegans. J Agric Food Chem. 2017 Oct 11;65(40):8855-8865. doi: 10.1021/acs.jafc.7b03224. Epub 2017 Sep 27.
21 Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem. 1993 Dec;61(6):2314-7. doi: 10.1111/j.1471-4159.1993.tb07476.x.
22 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
23 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int Immunol. 2005 May;17(5):599-606. doi: 10.1093/intimm/dxh242. Epub 2005 Mar 31.
24 Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin IIb3-mediated signaling in human platelets. Toxicol Appl Pharmacol. 2019 Feb 1;364:106-113. doi: 10.1016/j.taap.2018.12.016. Epub 2018 Dec 25.
25 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
27 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
28 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
29 Company report (NeurAxon)
30 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
31 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
32 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
33 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
34 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
35 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
36 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
37 Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
38 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
39 Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6.
40 Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9.
41 Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
42 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
43 Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67.
44 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
45 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
46 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
47 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
48 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
49 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
50 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
51 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
52 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
53 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
54 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
55 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
56 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
57 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
58 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
59 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
60 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
61 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
62 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
63 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
64 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
65 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
66 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
67 Clinical pipeline report, company report or official report of Lundbeck.
68 A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
69 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
70 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
71 2011 Pipeline of Can-Fite BioPharm.
72 Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
73 Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
74 Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
75 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
76 The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
77 Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
78 Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
79 Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
80 Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
81 Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
82 Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
83 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
84 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
85 The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
86 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
87 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
88 The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
89 A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
90 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
91 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
92 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
93 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
94 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
95 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
96 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
97 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
98 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
99 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
100 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
101 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
102 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
103 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
104 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
105 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
106 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
107 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
108 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
109 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
110 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
111 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
112 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
113 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
114 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
115 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
116 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
117 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
118 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
119 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
120 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
121 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
122 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
123 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
124 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
125 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
126 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
127 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
128 The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97.
129 Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131.
130 Gastrin-producing endocrine cells: a novel source of histamine in the rat stomach. Endocrinology. 1998 Oct;139(10):4404-15.
131 Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol. 2019 Apr 15;849:75-83.
132 Metformin: from mechanisms of action to therapies. Cell Metab. 2014 Dec 2;20(6):953-66.
133 Serotonin transporter gene and treatment of alcoholism.
134 Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
135 Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
136 Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
137 Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
138 Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
139 Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005 Nov 25;389(1):12-6. doi: 10.1016/j.neulet.2005.06.048.
140 Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. doi: 10.1017/S1461145703003663.
141 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
142 Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.
143 Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
144 Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
145 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
146 Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J Med Chem. 2011 Sep 22;54(18):6305-18. doi: 10.1021/jm200682b. Epub 2011 Aug 23.
147 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
148 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
149 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
150 Evidence for a role of claudin 2 as a proximal tubular stress responsive paracellular water channel. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):163-72.
151 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
152 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
153 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
154 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
155 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
156 Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
157 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
158 Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
159 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
160 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
161 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
162 The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
163 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
164 Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
165 Transcriptomic?pathway?and?benchmark dose analysis of Bisphenol A, Bisphenol S, Bisphenol F, and 3,3',5,5'-Tetrabromobisphenol A in H9 human embryonic stem cells. Toxicol In Vitro. 2021 Apr;72:105097. doi: 10.1016/j.tiv.2021.105097. Epub 2021 Jan 18.
166 Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
167 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
168 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
169 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
170 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
171 Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
172 Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 2003 Dec 1;60(3):518-28. doi: 10.1016/j.cardiores.2003.09.015.
173 Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
174 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
175 Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
176 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
177 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
178 Nephrotoxicity induced by cisplatin is primarily due to the activation of the 5-hydroxytryptamine degradation system in proximal renal tubules. Chem Biol Interact. 2021 Nov 1;349:109662. doi: 10.1016/j.cbi.2021.109662. Epub 2021 Sep 21.
179 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
180 Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
181 Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
182 Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
183 Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
184 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
185 Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
186 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
187 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
188 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
189 Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
190 Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
191 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
192 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
193 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
194 Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
195 Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun. 2004 Oct 22;323(3):782-8.
196 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
197 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
198 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
199 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
200 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
201 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
202 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
203 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
204 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
205 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
206 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
207 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
208 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
209 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
210 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
211 Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
212 [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
213 Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
214 Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Front Microbiol. 2015 Dec 22;6:1452. doi: 10.3389/fmicb.2015.01452. eCollection 2015.
215 Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 1998 Nov 15;102(10):1866-73. doi: 10.1172/JCI3692.
216 Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
217 Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
218 The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
219 Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001 Jun 1;97(11):3466-9. doi: 10.1182/blood.v97.11.3466.
220 Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. J Immunother. 2005 Jan-Feb;28(1):28-39. doi: 10.1097/00002371-200501000-00004.
221 -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
222 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
223 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
224 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
225 Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
226 Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
227 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
228 Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
229 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
230 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
231 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
232 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
233 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
234 Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
235 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
236 The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
237 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
238 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
239 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
240 Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
241 Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513. doi: 10.1016/j.taap.2021.115513. Epub 2021 Mar 27.
242 Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9. doi: 10.1038/sj.npp.1300637.
243 Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016 Oct 14;291(42):22053-22062. doi: 10.1074/jbc.M116.749119. Epub 2016 Aug 23.
244 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
245 Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100. doi: 10.1016/j.neuro.2019.02.011. Epub 2019 Feb 15.
246 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
247 Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97. doi: 10.1016/j.taap.2005.06.003. Epub 2005 Jul 11.
248 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
249 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
250 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
251 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
252 Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
253 Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
254 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
255 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
256 Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
257 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
258 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
259 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
260 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
261 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
262 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
263 Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
264 Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
265 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.